Your Biopharmaceutical Development and Manufacturing Partner

Nanotherapeutics Awarded $30.9 Million NIAID Contract to Develop Inhaled Antiviral for Prophylaxis and Treatment of Smallpox

Business Wire - August 2009

Nanotherapeutics, Inc., has been awarded a $30.9 Million, 5-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop an inhaled version of the injectable antiviral drug, cidofovir, for non-invasive, post-exposure prophylaxis and treatment of the Category A bioterrorism agent smallpox (Variola major).

Full Article

Copyright 2017 NANOTHERAPEUTICS, INC.  All rights reserved.